Phosphodiesterase 3A and Phosphodiesterase 3B (PDE3A and PDE3B)

Phosphodiesterase 3A and Phosphodiesterase 3B (PDE3A/B) are closely related enzymes of the phosphodiesterase 3 family that regulate intracellular levels of cyclic nucleotides, primarily cAMP and, to a lesser extent, cGMP[1][3][4]. PDE3A and PDE3B play key roles in controlling cardiac muscle contraction, vascular smooth muscle relaxation, and platelet aggregation[1][2][3]. PDE3A is especially important in cardiovascular tissues and platelets, while PDE3B is relevant in metabolic tissues such as adipose tissue and the liver[3]. Both enzymes contain conserved catalytic domains and regulatory regions, including family-specific phosphorylation sites that modulate their activity[2][3]. PDE3 inhibitors are used therapeutically for acute heart failure and intermittent claudication but are associated with significant safety risks including arrhythmia and increased mortality in chronic use[1]. The genes encoding these enzymes and their activity are important research and therapeutic targets in cardiovascular and metabolic diseases[1][2][3][4].

Other names

cGMP-inhibited cAMP phosphodiesterasecGMP-inhibited phosphodiesterase 3PDE3 family

Inhibitors block hydrolysis of cAMP and/or cGMP, leading to increased intracellular cyclic nucleotide concentrations, which results in enhanced cardiac contractility, vasodilation, and inhibition of platelet aggregation[1][4]. Many drugs act as selective allosteric inhibitors of the PDE3 catalytic domain[1].